Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Cenderitide
CAPRICOR THERAPEUTICS, INC.
Heart Failure
2 trials -
Ceralasertib
United Therapeutics Europe Ltd
Gynaecological Cancers
1 trial -
Cesium-131 brachytherapy
GT Biopharma
Recurrent Brain Metastases
1 trial -
Cetuximab
United Therapeutics Europe Ltd
BRAF V600E Negative
1 trial -
ChAdOx1-HBV
Barinthus Biotherapeutics plc.
Hepatitis B
2 trials -
ChAdOx1-HBV
Barinthus Biotherapeutics plc.
Chronic Hepatitis B
1 trial -
ChAdOx1-HPV
Barinthus Biotherapeutics plc.
HPV Infection
1 trial -
ChAdOx1-MVA 5T4 vaccine
Barinthus Biotherapeutics plc.
Intermediate Risk Prostate Cancer
1 trial -
ChAdOx1-PCAQ
Barinthus Biotherapeutics plc.
Prostate Cancer
1 trial -
Chemotherapy + immunotherapy
Hunan Province Tumor Hospital
Non Small Cell Lung Cancer
1 trial -
Chemotherapy plus apatinib
Lei Li
Recurrent Cervical Carcinoma
1 trial -
Chemotherapy+PD-1 inhibitor+8Gy x 3f
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HR+HER2- Breast Cancer
1 trial -
Chidamide
Sun Yat-sen University
Peripheral T-cell Lymphoma
1 trial -
Chidamide
Biotech Pharmaceutical Co.,
Relapsed or Refractory Peripheral T-cell Lymphoma
1 trial -
Chidamide + Tislelizumab + chemotherapy (CapeOX )
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colon Adenocarcinoma
1 trial -
Chidamide Combined with NKG2D CAR-NK Cell Therapy
The First People's Hospital of Lianyungang
HIV (Human Immunodeficiency Virus)
1 trial -
Chidamide combined with Duvillisib
The First People's Hospital of Lianyungang
Peripheral T Cell Lymphoma
1 trial -
Chinese herbal therapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Urinary Incontinence, Stress
1 trial -
Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early relapsed metastatic triple-negative breast cancer
The George Institute
Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.
1 trial -
Ciclosporin
United Therapeutics Europe Ltd
Myocardial Reperfusion Injury
1 trial -
Ciprofloxacin
United Therapeutics Europe Ltd
Crohn's Disease
1 trial -
Claseprubart
Dianthus Therapeutics, Inc. /DE/
Multifocal Motor Neuropathy
1 trial -
Clobetasol Propionate
United Therapeutics Europe Ltd
Colon Adenocarcinoma
1 trial -
Clonidine
Grace Therapeutics
Pregnancy Related
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources